ASX Announcement

20 February 2024

RHYTHM BIOSCIENCES

PAC Partners Appointed Lead Manager

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to announce that it has appointed PAC Partners Securities Pty Limited (**PAC Partners**) in relation to its entitlement offering to existing shareholders (**Rights Issue**).

PAC Partners primary role will be acting as the sole bookrunner in seeking investor commitments to secure investment in the Company on the same terms as the Rights Issue for entitlements not subscribed for (if any) by existing shareholders (Shortfall Shares).

Participation in Shortfall Shares (if any)

Parties seeking to commit to participating in the take-up of Shortfall Shares (if any) from Rhythm's Rights Issue Offer should register their interest with PAC Partners principal Sean Kennedy at <u>corporate@pacpartners.com.au</u>.

Otto Buttula, Executive Chairman of Rhythm, commented "We are pleased to have entered into this mandate with PAC Partners, a company we have known for some time and who have a strong understanding of the opportunities ahead for our simple, inexpensive portfolio of diagnostics tests, commencing with our most advanced technology ColoSTAT[®]. Importantly it provides a centralised source for investor inquiry with a leading, independent equities provider, experienced in life sciences; thereby allowing the Rhythm team to continue to focus upon advancing its manufacturing, regulatory and commercialisation activities."

Authorisation & Additional Information

This announcement was authorised by the Board of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com:

Mr. Otto Buttula	Mr. Guy Carisbrooke	Mr. James Barrie
Executive Chairman	Financial Controller	Joint Company Secretary

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

Rhythm Biosciences Ltd ACN 619 459 335 ASX: RHY Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute 30 Flemington Road Parkville VIC 3010 Australia Directors Otto Buttula Sue MacLeman

Trevor Lockett Louis Panaccio Executive Chairman Non-Executive Independent Deputy Chair Non-Executive Director Non-Executive Director

www.rhythmbio.com

T +61 3 8256 2880 E info@rhythmbio.com

RHYTHM BIOSCIENCES

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT[®] Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About PAC Partners

PAC Partners is a leading independent financial services group, where most of the partners & owners have worked together +20 years.

PAC Partners provides equities research and cooperation on corporate advisory and equity capital markets transactions; and also providing institutional and high net worth client distribution. PAC Partners focuses on leading emerging and mid-cap companies with Corporate Finance clients include some of Australia's highest potential growth companies.

PAC Partners:

- ✓ is a leading, independent equities provider in Australia;
- ✓ services the Institutional and Wholesale investment markets, both in Australia and across Asia; and
- ✓ is consistently one of the most active independent capital markets providers in Australia, focusing on leading emerging and mid-cap companies through long-term and deep relationships.

www.pacpartners.com.au or enquiries@pacpartners.com.au